Se connecter Inscription gratuite

4SC AG Transmettre P/E

Quel est le Transmettre P/E de 4SC AG?

Le Transmettre P/E de 4SC AG est -2.94

Quelle est la définition de Transmettre P/E?



Le ratio prix à terme/bénéfice est le rapport entre le prix des actions d'une société et son bénéfice par action estimé pour les douze prochains mois.

The forward price to earnings ratio is similar to trailing price to earnings ratio but instead of net income uses estimated net earnings over next 12 months. Estimates are typically derived as the mean of those published by a select group of analysts with selection criteria varying. The forward price-to-earnings ratio is a powerful, but limited tool. It allows a quick snapshot of the company’s finances without getting down in the details of an accounting report.

Transmettre P/E des entreprises dans Health Care secteur sur XETRA par rapport à 4SC AG

Que fait 4SC AG?

4SC AG, a clinical-stage biopharmaceutical company, engages in developing small-molecule drugs that target key indications in cancer with high unmet medical needs. The company's products in clinical development stage include Resminostat, an orally administered histone deacetylase inhibitor that is in Phase II clinical trial for the treatment of cutaneous T-cell lymphoma; and Domatinostat, an orally administered small molecule, which is in Phase Ib/II clinical trial for the treatment of melanoma and Phase II clinical trial for the treatment of gastrointestinal tumor. 4SC AG also out-licenses its products to pharma and biotech companies for the treatment of cancer. The company has a collaboration agreement with the Netherlands Cancer Institute to evaluate Domatinostat in the neoadjuvant setting in melanoma. 4SC AG was founded in 1997 and is headquartered in Planegg, Germany.

Entreprises avec transmettre p/e similaire à 4SC AG